针对相关多重耐药病原体的噬菌体疗法进展
Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens.
作者信息
Broncano-Lavado Antonio, Santamaría-Corral Guillermo, Esteban Jaime, García-Quintanilla Meritxell
机构信息
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain.
出版信息
Antibiotics (Basel). 2021 Jun 4;10(6):672. doi: 10.3390/antibiotics10060672.
Abstract
The increase of multiresistance in bacteria and the shortage of new antibiotics in the market is becoming a major public health concern. The World Health Organization (WHO) has declared critical priority to develop new antimicrobials against three types of bacteria: carbapenem-resistant , carbapenem-resistant and carbapenem-resistant and ESBL-producing . Phage therapy is a promising alternative therapy with renewed research in Western countries. This field includes studies in vitro, in vivo, clinical trials and clinical cases of patients receiving phages as the last resource after failure of standard treatments due to multidrug resistance. Importantly, this alternative treatment has been shown to be more effective when administered in combination with antibiotics, including infections with biofilm formation. This review summarizes the most recent studies of this strategy in animal models, case reports and clinical trials to deal with infections caused by resistant , , and strains, as well as discusses the main limitations of phage therapy.
摘要
细菌多重耐药性的增加以及市场上新抗生素的短缺正成为一个主要的公共卫生问题。世界卫生组织（WHO）已宣布将开发针对三种类型细菌的新型抗菌药物列为关键优先事项：耐碳青霉烯类、耐碳青霉烯类以及耐碳青霉烯类且产超广谱β-内酰胺酶（ESBL）的细菌。噬菌体疗法是一种有前景的替代疗法，在西方国家正重新受到研究。该领域包括体外研究、体内研究、临床试验以及因多重耐药导致标准治疗失败后将噬菌体作为最后手段的患者临床病例。重要的是，这种替代疗法已被证明与抗生素联合使用时更有效，包括对形成生物膜的感染。本综述总结了该策略在动物模型、病例报告和临床试验中针对由耐药的、、和菌株引起的感染的最新研究，并讨论了噬菌体疗法的主要局限性。
相似文献
1
Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens.针对相关多重耐药病原体的噬菌体疗法进展
Antibiotics (Basel). 2021 Jun 4;10(6):672. doi: 10.3390/antibiotics10060672.
2
[Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails].[引起复杂性皮肤和软组织感染的多重耐药病原体对标准噬菌体鸡尾酒疗法的敏感性]
Mikrobiyol Bul. 2016 Apr;50(2):215-23. doi: 10.5578/mb.24165.
3
Patterns of Drug-Resistant Bacteria in a General Hospital, China, 2011-2016.2011 - 2016年中国某综合医院耐药菌模式
Pol J Microbiol. 2019;68(2):225-232. doi: 10.33073/pjm-2019-024.
4
5
[Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].[2005年至2009年期间，贝鲁特一家大学医院中心大肠杆菌、肺炎克雷伯菌、铜绿假单胞菌和鲍曼不动杆菌对抗生素敏感性的演变]
Pathol Biol (Paris). 2012 Jun;60(3):e15-20. doi: 10.1016/j.patbio.2011.03.011. Epub 2011 Jun 29.
6
Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.双管齐下对抗致病菌：噬菌体与抗生素联合策略。
Front Cell Infect Microbiol. 2019 Feb 18;9:22. doi: 10.3389/fcimb.2019.00022. eCollection 2019.
7
Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.鲍曼不动杆菌、铜绿假单胞菌和肺炎克雷伯菌引起的碳青霉烯类和多黏菌素耐药菌血症的流行率和 30 天全因死亡率：长达十年趋势的描述。
Int J Infect Dis. 2019 Aug;85:10-15. doi: 10.1016/j.ijid.2019.05.004. Epub 2019 May 14.
8
The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.接种物量对头孢哌酮-舒巴坦对多药耐药菌活性的影响。
J Microbiol Immunol Infect. 2018 Apr;51(2):207-213. doi: 10.1016/j.jmii.2017.08.026. Epub 2017 Oct 6.
9
Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.作为替加环素评估与监测试验的一部分，2004年至2014年期间替加环素对多重耐药革兰氏阴性病原菌活性的全球评估
mSphere. 2017 Jan 18;2(1). doi: 10.1128/mSphere.00310-16. eCollection 2017 Jan-Feb.
10
Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant in Mice.噬菌体疗法作为一种有前景的新型治疗方法用于治疗小鼠耐碳青霉烯类药物引起的肺部感染。
Front Microbiol. 2018 Jan 9;8:2659. doi: 10.3389/fmicb.2017.02659. eCollection 2017.
引用本文的文献
1
Dual Nature of Bacteriophages: Friends or Foes in Minimally Processed Food Products-A Comprehensive Review.噬菌体的双重性质：即最低限度加工食品中的朋友还是敌人——一篇综述
Viruses. 2025 May 29;17(6):778. doi: 10.3390/v17060778.
2
Characterization and genome analyses of the novel phages targeting extraintestinal Escherichia coli clones ST131 and ST410.针对肠外大肠杆菌克隆ST131和ST410的新型噬菌体的特性分析和基因组分析
Int Microbiol. 2025 Jun 20. doi: 10.1007/s10123-025-00686-z.
3
Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.多重耐药性胃肠道感染的非抗生素疗法：益生菌、天然化合物和噬菌体的应用概述
Front Antibiot. 2025 May 6;4:1554061. doi: 10.3389/frabi.2025.1554061. eCollection 2025.
4
In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii.体外实验中，一种新型热稳定裂解性奥博连斯克病毒噬菌体的基因组特征分析及临床前评估，该噬菌体被制成水凝胶用于对抗耐碳青霉烯鲍曼不动杆菌。
Sci Rep. 2025 May 17;15(1):17149. doi: 10.1038/s41598-025-99788-x.
5
Characterization and purification of Pseudomonas aeruginosa phages for the treatment of canine infections.用于治疗犬类感染的铜绿假单胞菌噬菌体的特性鉴定与纯化
BMC Microbiol. 2025 May 14;25(1):289. doi: 10.1186/s12866-025-04005-4.
6
Bacteriophage Therapy as a Promising Alternative for Antibiotic-Resistant : Advances and Challenges.噬菌体疗法作为抗生素耐药性的一种有前景的替代方法：进展与挑战
Antibiotics (Basel). 2024 Nov 23;13(12):1120. doi: 10.3390/antibiotics13121120.
7
Isolation and characterization of bacteriophages targeting methicillin-resistant Staphylococcus aureus (MRSA) from burn patients and sewage water: a genomic and proteomic study.从烧伤患者和污水中分离并鉴定靶向耐甲氧西林金黄色葡萄球菌（MRSA）的噬菌体：一项基因组学和蛋白质组学研究。
Int Microbiol. 2024 Dec 6. doi: 10.1007/s10123-024-00618-3.
8
Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.用于对抗临床相关病原体的噬菌体治疗递送方法及临床试验。
Ther Deliv. 2025 Mar;16(3):247-269. doi: 10.1080/20415990.2024.2426824. Epub 2024 Nov 15.
9
Transmission Dynamics and Novel Treatments of High Risk Carbapenem-Resistant : The Lens of One Health.高风险耐碳青霉烯类药物的传播动力学与新疗法：“同一健康”视角
Pharmaceuticals (Basel). 2024 Sep 12;17(9):1206. doi: 10.3390/ph17091206.
10
Bacteriophage Therapy on an In Vitro Wound Model and Synergistic Effects in Combination with Beta-Lactam Antibiotics.噬菌体疗法对体外伤口模型的作用及与β-内酰胺类抗生素联合使用的协同效应
Antibiotics (Basel). 2024 Aug 24;13(9):800. doi: 10.3390/antibiotics13090800.
本文引用的文献
1
Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease.个性化噬菌体疗法治疗慢性阻塞性肺疾病患者耐碳青霉烯类肺部感染的临床经验
Front Cell Infect Microbiol. 2021 Feb 26;11:631585. doi: 10.3389/fcimb.2021.631585. eCollection 2021.
2
Pre-optimized phage therapy on secondary infection in four critical COVID-19 patients.针对 4 名危重症 COVID-19 患者的继发感染进行了预先优化的噬菌体治疗。
Emerg Microbes Infect. 2021 Dec;10(1):612-618. doi: 10.1080/22221751.2021.1902754.
3
Identification and complete genome of lytic "Kp34likevirus" phage vB_KpnP_Bp5 and therapeutic potency in the treatment of lethal Klebsiella pneumoniae infections in mice.裂解性“Kp34likevirus”噬菌体vB_KpnP_Bp5的鉴定、全基因组及对小鼠致死性肺炎克雷伯菌感染的治疗效力
Virus Res. 2021 May;297:198348. doi: 10.1016/j.virusres.2021.198348. Epub 2021 Feb 22.
4
Bacteriophage Treatment Rescues Mice Infected with Multidrug-Resistant Klebsiella pneumoniae ST258.噬菌体治疗挽救感染多重耐药肺炎克雷伯菌 ST258 的小鼠。
mBio. 2021 Feb 23;12(1):e00034-21. doi: 10.1128/mBio.00034-21.
5
Phages from Ganges River curtail in vitro biofilms and planktonic growth of drug resistant Klebsiella pneumoniae in a zebrafish infection model.来自恒河的噬菌体在斑马鱼感染模型中可抑制耐药性肺炎克雷伯菌的体外生物膜形成和浮游生长。
AMB Express. 2021 Feb 15;11(1):27. doi: 10.1186/s13568-021-01181-0.
6
Heterogeneous Co-infections Complicate Personalized Bacteriophage Therapy.异源共感染使个性化噬菌体治疗复杂化。
Front Cell Infect Microbiol. 2021 Jan 25;10:608402. doi: 10.3389/fcimb.2020.608402. eCollection 2020.
7
Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials.耐噬菌体鲍曼不动杆菌对抗菌药物重新敏感。
Nat Microbiol. 2021 Feb;6(2):157-161. doi: 10.1038/s41564-020-00830-7. Epub 2021 Jan 11.
8
Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.噬菌体 PEV20-环丙沙星联合粉末制剂的协同作用：在铜绿假单胞菌肺部感染模型中的原理研究。
Eur J Pharm Biopharm. 2021 Jan;158:166-171. doi: 10.1016/j.ejpb.2020.11.019. Epub 2020 Nov 27.
9
Isolation and Characterization of a Novel Myophage Abp9 Against Pandrug Resistant .一种新型抗泛耐药性肌噬菌体Abp9的分离与鉴定
Front Microbiol. 2020 Sep 8;11:506068. doi: 10.3389/fmicb.2020.506068. eCollection 2020.
10
Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States.从美国一家中心连续治疗多药耐药细菌感染的首例10例静脉注射噬菌体疗法中吸取的经验教训。
Open Forum Infect Dis. 2020 Aug 27;7(9):ofaa389. doi: 10.1093/ofid/ofaa389. eCollection 2020 Sep.
Zotero 插件